Drug side effects
netarsudil Side Effects
The reactions most often reported to the FDA for netarsudil (also sold as Rhopressa), with demographics, serious outcomes, and reporting trends.
Data updated 2026-05-15
- 1,797
- FAERS reports
Data from the FDA Adverse Event Reporting System (FAERS), 2017 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.
The most commonly reported side effects of netarsudil come from 1,797 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.
This page analyzes 1,797 reports to the FDA Adverse Event Reporting System (FAERS) for netarsudil (Rhopressa): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.
Total Reports
1,797
Reports Mentioning Death
56
3.1% of reports — not proof the medicine caused the death
Hospitalizations
97
5.4% of reports
Top Indication
Glaucoma
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 56 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 49 |
| ACUTE MYELOID LEUKAEMIA | 3 |
| ACUTE RESPIRATORY FAILURE | 1 |
| AGITATION | 1 |
| ARTERIOSCLEROSIS | 1 |
| BLOOD CHLORIDE DECREASED | 1 |
| BLOOD CREATININE DECREASED | 1 |
| BLOOD GLUCOSE DECREASED | 1 |
| BLOOD POTASSIUM DECREASED | 1 |
| BLOOD SODIUM DECREASED | 1 |
| BODY HEIGHT DECREASED | 1 |
| CARDIAC FAILURE CONGESTIVE | 1 |
| CYTOKINE RELEASE SYNDROME | 1 |
| DEMENTIA | 1 |
| DYSPNOEA | 1 |
| FALL | 1 |
| FATIGUE | 1 |
| HALLUCINATION | 1 |
| HYPOTENSION | 1 |
| HYPOXIA | 1 |
Reactions in Hospitalization Reports
Top reactions in 97 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| PLEURAL EFFUSION | 10 |
| FATIGUE | 8 |
| FALL | 7 |
| GENERALISED OEDEMA | 7 |
| NAUSEA | 6 |
| CARDIAC FAILURE CONGESTIVE | 5 |
| DEATH | 5 |
| DIARRHOEA | 5 |
| CEREBROVASCULAR ACCIDENT | 4 |
| CONSTIPATION | 4 |
| DYSPNOEA | 4 |
| HAEMOGLOBIN DECREASED | 4 |
| THERAPY INTERRUPTED | 4 |
| VISUAL IMPAIRMENT | 4 |
| WEIGHT DECREASED | 4 |
| ANXIETY | 3 |
| ARTHRALGIA | 3 |
| ASTHENIA | 3 |
| BLOOD GLUCOSE DECREASED | 3 |
Nearby, Related Medications
What the FAERS Data Reveals About netarsudil Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 1,797 voluntary reports linked to netarsudil and its brand equivalents (Rhopressa), spanning 2017 through 2025. Of those, 56 (3.1%) listed death as an outcome and 97 (5.4%) involved hospitalization. The most common indication reported alongside adverse events was Glaucoma.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 61% were female and 39% male; age distribution skews toward 75+, with 326 reports in that bracket. The single most reported reaction is conjunctival hyperaemia with 244 submissions, followed by vision blurred and eye pain.
How to read these numbers
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.
Drugs With a Similar FAERS Report Volume
Other medications with a total FDA adverse-event report count closest to netarsudil's 1,797.
Read our methodology - how this data is sourced, computed, and verified.